Table 2 Patient demographic and clinical characteristics
Dose-escalation cohort ( n =16) | ||||
|---|---|---|---|---|
Characteristic | Dose level 1 ( n =6) | Dose level 2 ( n =10) | Expansion cohort ( n =14) | Total ( n =30) |
Sex | ||||
Male | 2 | 5 | 8 | 15 |
Female | 4 | 5 | 6 | 15 |
Age, years | ||||
Median (range) | 67.5 (57–75) | 62 (44–82) | 59 (37–75) | 62 (37–82) |
ECOG performance status | ||||
0 | 4 | 4 | 4 | 12 |
1 | 2 | 6 | 10 | 18 |
Prior chemotherapy regimens | ||||
0–1 | 0 | 2 | 3 | 5 |
2 | 0 | 2 | 0 | 2 |
3+ | 6 | 6 | 11 | 23 |
Tumour type | ||||
Adrenal | 1 | 1 | ||
Biliary | 1 | 1 | 3 | |
Basal cell carcinoma | 1 | 1 | ||
Breast | 1 | 1 | ||
Colorectal | 3 | 1 | 4 | 8 |
Cervical | 1 | 1 | ||
Pancreatic | 2 | 2 | 3 | |
Prostate | 1 | 1 | ||
Sarcoma | 1 | 2 | 3 | |
Thyroid | 2 | 2 | 4 | |
Tongue (SCC) | 1 | 2 | 3 | |
Urethral | 1 | 1 | ||
